Chongqing Zhifei Biological Products (300122.SZ): The herpes zoster mRNA vaccine has been approved for clinical trials.

16:05 03/02/2026

Chifeng Biology (300122.SZ) announced that its subsidiary Anhui Chifeng Dragon Pharma Biotech Co., Ltd. (referred to as "Chifeng Dragon Pharma") has obtained the notification of approval for clinical trials of herpes zoster mRNA vaccine from the National Medical Products Administration, allowing for clinical trials to prevent herpes zoster.

Chongqing Zhifei Biological Products (300122.SZ) announced that its subsidiary Anhui Zhifeilong Kema Bio-Pharmaceutical Co., Ltd. (referred to as "Zhifeilong Kema") has received approval from the National Medical Products Administration to conduct clinical trials for a herpes zoster mRNA vaccine developed by the company.

SHOUGANG C-NEW (00103) on February 3 spent about 59,800 Hong Kong dollars to repurchase 20,000 shares.

Goldwind Science & Technology (02208) has not repurchased any A shares as of January 31st.

GRAPHEX GROUP (06128) subsidiary plans to acquire a 40% stake in Chuangchi for 1.5 million Hong Kong dollars to expand its presence in the electric vehicle and related downstream battery business.

SHOUGANG C-NEW (00103) on February 3 spent about 59,800 Hong Kong dollars to repurchase 20,000 shares.

Goldwind Science & Technology (02208) has not repurchased any A shares as of January 31st.

GRAPHEX GROUP (06128) subsidiary plans to acquire a 40% stake in Chuangchi for 1.5 million Hong Kong dollars to expand its presence in the electric vehicle and related downstream battery business.